Managing youth with type 2 diabetes has its challenges in comparison to the adult population. Dr Silva Arslanian (University of Pittsburgh, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA) discusses these challenges as well as the effectiveness of lifestyle-focused interventions in younger patients with diabetes.
Dr Silva Arslanian presented an abstract entitled ‘Dulaglutide in Youth with Type 2 Diabetes (T2D)—Results of the AWARD-PEDS Randomized, Placebo-Controlled Trial’ at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022.
- What are the current challenges in managing type 2 diabetes in younger people, compared with the adult population? (0:23)
- How effective are lifestyle-focused interventions in the younger diabetic population? (2:03)
Disclosures: Silva Arslanian is a consultant for and has received grant/research support from Novo Nordisk and Eli Lilly. Silva Arslanian is on the advisory board for the Data Monitoring Committee at AstraZeneca.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ADA 2022.
Share this Video
Related Videos In Paediatric Endocrinology
Bradley Miller, ESPE 2022: Advantages of Somapacitan versus Daily GH in Children with GH Deficiency
Daily growth hormone (GH) injections can be burdensome for patients and carers. Somapacitan is a long-acting, reversible albumin-binding GH derivative in development for once-weekly administration in patients with growth hormone deficiency (GHD). In this touchENDOCRINOLOGY interview, Prof. Bradley Miller (University of Minnesota, Minneapolis, MN, USA) discusses the challenges of GH therapy in children and the […]
Bradley Miller, ESPE 2022: Once-Weekly Somapacitan versus Daily GH in Children with GH Deficiency: The REAL 4 Trial
The REAL 4 trial is a multicenter, randomized, controlled, double-blind phase 3 study (NCT03811535) to evaluate the efficacy, safety, and tolerability of once-weekly somapacitan vs once-daily growth hormone (GH). In this touchENDOCRINOLOGY interview, Prof. Bradley Miller (University of Minnesota, Minneapolis, MN, USA) discusses the aims, design and results of the REAL 4 trial. The next […]
Uberto Pagotto, ESPE 2022: GLP-1 Agonists and Other Emerging Treatments of Obesity
Glucagon-like peptide-1 agonists are a class of medications utilized in the treatment of type 2 diabetes and obesity. In this touchENDOCRINOLOGY interview, Prof. Uberto Pagotto (University of Bologna, Bologna, Italy) discusses the impact of glucagon-like peptide 1 agonists on obesity, what other emerging treatments in obesity appear promising. The future direction in obesity research is […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!